Abstract
Dopamine is an important chemical messenger in the brain, which modulates movement, reward, motivation, and memory. Different populations of neurons can produce and release dopamine in the brain and regulate different behaviors. Here we focus our discussion on a small but distinct group of dopamine-producing neurons, which display the most profound loss in the ventral substantia nigra pas compacta of patients with Parkinson’s disease. This group of dopaminergic neurons can be readily identified by a selective expression of aldehyde dehydrogenase 1A1 (ALDH1A1) and accounts for 70% of total nigrostriatal dopaminergic neurons in both human and mouse brains. Recently, we presented the first whole-brain circuit map of these ALDH1A1-positive dopaminergic neurons and reveal an essential physiological function of these neurons in regulating the vigor of movement during the acquisition of motor skills. In this review, we first summarize previous findings of ALDH1A1-positive nigrostriatal dopaminergic neurons and their connectivity and functionality, and then provide perspectives on how the activity of ALDH1A1-positive nigrostriatal dopaminergic neurons is regulated through integrating diverse presynaptic inputs and its implications for potential Parkinson’s disease treatment.
Introduction
Parkinson’s disease (PD), the most common degenerative movement disorder, particularly affects basal ganglia dopamine transmission (; ). One of the most prominent pathological hallmarks of the disease is a preferential degeneration of dopaminergic neurons (DANs) located in the ventrolateral tier of substantia nigra pars compacta (SNc) (; ). While a member of aldehyde dehydrogenase family genes termed murine class 1 (cytosolic) aldehyde dehydrogenase (AHD2) or aldehyde dehydrogenase 1A1 (ALDH1A1) was reported some time ago to be selectively expressed by a subpopulation of DANs in the rodent ventral SNc (), it is until 20 years later that research in post-mortem human brains demonstrates a conserved topological distribution of ALDH1A1-positive DANs in the human SNc as well as a more severe loss of ALDH1A1-positive nigrostriatal DANs (ALDH1A1+ nDANs) in PD patients compared to the ALDH1A1-negative ones (). ALDH1A1 is a key enzyme to mediate the biosynthesis of retinoic acids () and catabolism of reactive dopamine metabolites (; ) in DANs. The reduction of ALDH1A1 expression may contribute to the etiopathogenesis of PD (; ; ; ), whereas an increase of ALDH1A1 levels protects against dopaminergic neurodegeneration (; ). Although the expression and biochemical function of ALDH1A1 protein is extensively documented, less is known regarding the molecular, electrophysiological, anatomical, and physiological properties of ALDH1A1+ nDANs. We believe that a further in-depth study of ALDH1A1+ nDANs will bridge the gap toward a cell-type specific understanding of neural circuit mechanisms and treatment of PD.
ALDH1A1 Defines and Protects a Nigrostriatal Dopaminergic Neuron Subpopulation
The nigrostriatal DANs are diverse in nature and can be categorized into groups of distinct subpopulations based on location, gene expression profiles, electrophysiological properties, morphology, projection pattern, physiological functions, and vulnerabilities to various diseases (; ; ; ; ; ). Traditionally, midbrain DANs can be divided into three main subgroups, retrorubral field (RRF, A8), SNc (A9), and ventral tegmental area (VTA, A10), in human and rodents (; ). In the post-mortem brains of PD patients, the most profound loss of DANs has been seen in the ventral tier of SNc (; ). Further studies have demonstrated that these ventral DANs can be molecularly defined by a selective expression of ALDH1A1 (; ). ALDH1A1 belongs to ALDH superfamily genes, which consist of 19 members in human genome () and 20 members in mouse genome (). ALDH1A1 is predominantly and highly expressed by the ventral DANs in human and mouse SNc, suggesting its distinctive role in the function and survival of ventral DANs (; ). As a multifunctional enzyme in DANs, ALDH1A1 mediates the synthesis of retinoic acids important for the differentiation of DANs during development (). ALDH1A1 is also suggested to conduct the alternative synthesis of inhibitory transmitter GABA in DANs (). More importantly, ALDH1A1 oxidizes the highly reactive dopamine catabolic intermediate dopamine-3,4-dihydroxyphenylacetaldehyde (DOPAL) and protects ALDH1A1+ nDANs against DOPAL-induced cytotoxicity (; ). A recent study suggests that DOPAL can be actively produced in DANs when the monoamine oxidase (MAO)-mediated dopamine oxidation is employed in ATP production in mitochondria (). DOPAL is highly reactive and a lack of ALDH1A1 may lead to accumulation of DOPAL, which has been shown to promote cytotoxic polymerization of PD-related α-synuclein and compromise the functions of proteins important in the activity and survival of DANs (). Accordingly, ALDH1A1+ nDANs are less vulnerable to α-synuclein–mediated neurodegeneration compared with the ALDH1A1-negative ones in α-synuclein transgenic mice, while genetic deletion of Aldh1a1 exacerbates DAN loss (). Downregulation of ALDH1A1 mRNA and protein levels along with severe loss of DANs has also been reported in the ventral SNc of post-mortem PD brains (; ; ). The reduction of ALDH1A1 expression in PD may weaken the protective function of ALDH1A1 in the ventral tier of SNc and predispose these neurons to degeneration at the later stages of disease (). Therefore, a profound reduction of ALDH1A1 expression may represent the turning point toward pathogenicity of ventral SNc DANs undergoing neurodegeneration in PD and ALDH1A1 expression level and activity may be extrapolated as a useful biomarker to monitor the progression of the disease as well as potential therapeutic targets ().
The ALDH1A1+ DANs account for 63% of SNc, 32% of VTA and 5% of RRF DANs in mouse brains (). The ALDH1A1+ DANs also make up for 72% of SNc DANs in human brains (), while the percentages in other midbrain brain regions remain to be determined. The ALDH1A1+ DANs in VTA regions exhibit distinct connectivity patterns compared to their counterparts in SNc (); however, little is known about their functional contribution to any behavioral phenotypes. Therefore, we focused the present review on the SNc ALDH1A1+ DANs only.
Molecular Characteristics of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons
The ALDH1A1+ nDANs are closely clustered in the ventral tier of SNc (). The most distinctive genetic markers for this subtype of DANs in rodents are Aldh1a1 (; ; ) and Aldh1a7 (). The Aldh1a7 gene is located next to the Aldh1a1 in the mouse chromosome 19 and is highly homologous to the Aldh1a1. Aldh1a7 gene is absent in the human genome, which may contribute to the higher sensitivity of human DANs to dopamine-related cytotoxicity and PD-related genetic insults (; ). Recently, single-cell RNA-sequencing (scRNA-seq) in combination with various mRNA fluorescence in situ hybridization methods provide unprecedented molecular details for diverse DAN subpopulations at different developmental stages (; ; ; ; ). A number of genes are highly correlated with the Aldh1a1 expression in the rodent DANs (), including Lmo3, Cdh8, Serpine2, Ptpn5, and Aldh1a7 (Figure 1A), which also display a similarly restricted expression pattern in the ventral SNc as Aldh1a1 mRNAs in mouse brains (Allen Brain Atlas) (Figure 1B), indicating these genes are among the molecular signature of ALDH1A1+ nDANs. By contrast, there is no or extremely low expression of calbindin in the ALDH1A1+ nDANs (; ), which may serve as a useful marker for ALDH1A1-negative nigrostriatal DANs. In a recent scRNA-seq study with postnatal day 60 to 70 mouse brain, Vglut2, Cbln4, Neurod6, and Tacr3 were added as additional markers for the mature ALDH1A1+ nDANs (). Moreover, based on the unique expression of Vcan, Anxa1, and Grin2C, the ALDH1A1+ nDANs can be further divided into three sub-populations (). The gene expression studies lay the foundation for later functional characterization of distinct ALDH1A1+ nDANs subpopulations under normal and disease-related conditions.
FIGURE 1
Electrophysiological Properties of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons
ALDH1A1+ nDANs exhibit distinct electrophysiological properties and rebound more readily from hyperpolarization (
FIGURE 2

Electrophysiological characteristics of ALDH1A1+ nDANs. (A) Two-photon image of a ALDH1A1+ nDAN. (B) Average calcium transient (above) and action potential (below) shape during tonic firing for a ALDH1A1+ nDAN. (C) Hyperpolarization-dependent after depolarizations (above) and corresponding dendritic calcium transients (below) for a ALDH1A1+ nDAN. (D) Amplitude of the calcium transient from a potential of −80 mV graphed by the area under the curve (AUC) for the corresponding low-threshold depolarization. Calb–, Calbindin-negative population (data re-graphed from
FIGURE 3

Distinct electrophysiology, connectivity, and functionality of ALDH1A1+ nDANs. (A) Rebound activity of ALDH1A1+ nDANs following dSPN inhibition. (B) Major inhibitory and excitatory presynaptic inputs to the ALDH1A1+ nDANs. (C) A critical involvement of ALDH1A1+ nDANs in regulating the vigor of movement during the acquisition of motor skills.
Projection Pattern of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons
The ALDH1A1+ nDANs exhibit a distinct projection pattern in the rostral and dorsal portions of dorsal striatum (DS), including both the dorsomedial striatum (DMS) and dorsolateral striatum (DLS) (
Monosynaptic Inputs Onto ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons
ALDH1A1-positive DANs receive the majority of monosynaptic inputs from the striatum (
Dopamine Release Dynamics of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons
There has been no direct quantification of dopamine release from the axon terminals of ALDH1A1+ nDAN in DS. Since ALDH1A1-positive dopaminergic axons converge onto striosome compartments in the DLS (
Physiological Function of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons
It has been generally accepted that the nigrostriatal DAN-mediated dopamine transmission is essential in regulating the vigor of movement (
ALDH1A1+ nDANs are also implicated in motor skill learning (
Systemic administration of levodopa or dopamine receptor agonists allows the ALDH1A1+ nDAN-ablated mice to walk faster but fail to improve the motor skill learning (
Functional Regulation of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons
ALDH1A1+ nDANs receive monosynaptic inhibitory GABAergic inputs from DS, external globus pallidus (GPe) and other brain regions (
The subthalamic nucleus (STN), cortex, and pedunculopontine nucleus (PPN) all provide excitatory inputs to the ALDH1A1+ nDANs, but the major source of excitatory input to ALDH1A1+ nDANs comes from neurons projecting from the STN (
Conclusion and Future Perspectives
Previous studies demonstrate that ALDH1A1+ nDANs are preferentially degenerated in PD, the most common degenerative movement disorder (
The importance of regulated dopamine release by nigrostriatal DANs, particularly ALDH1A1+ nDANs, may explain why so many therapies for PD that largely focus on simply supplementing lost dopamine fail to fully restore behavioral deficits in patients, including learning and memory deficits (
The revelation of preferential vulnerability of ALDH1A1+ nDANs in PD promotes ongoing efforts in understanding cell-type and neural circuit specific mechanism of the disease. By taking advantage of newly developed single cell RNA sequencing, CRISPR/Cas9 gene editing, optogenetics, chemogenetics, and live imaging with genetically encoded indicators techniques, we expect that increasing knowledge will be gained on how different subtypes of DANs contribute to different aspects of behavioral phenotypes. A further emphasis on system and behavioral neuroscience may provide new mechanistic insights into designing novel therapeutic strategies for PD treatment.
Statements
Author contributions
HC outlined the article, wrote the introduction, physiology, function, and perspectives sections, as well as prepared the figures. KC wrote the main regulation and conclusion sections. EL contributed to the regulation section. MK contribute to introduction section. LS wrote the molecule section. JD contributed to the gene expression analyses. RCE and ZMK contributed to the electrophysiology analyses. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by the Intramural Research Programs of National Institute on Aging, NIH (HC, ZIA AG000944, AG000928).
Acknowledgments
We are indebted to the suggestions and comments from other Cai lab members.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
BeelerJ. A.FrankM. J.McDaidJ.AlexanderE.TurksonS.Bernardez SarriaM. S.et al (2012). A role for dopamine-mediated learning in the pathophysiology and treatment of Parkinson’s disease.Cell Rep.21747–1761. 10.1016/j.celrep.2012.11.014
2
BentivoglioM.MorelliM. (2005). The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain.Dopamine211–107. 10.1016/S0924-8196(05)80005-3
3
BurkeR. E. (2010). Intracellular signalling pathways in dopamine cell death and axonal degeneration.Progress Brain Res.18379–97. 10.1016/S0079-6123(10)83005-5
4
CaiH.LiuG.SunL.DingJ. (2014). Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson’s disease.Transl. Neurodegener.3:27. 10.1186/2047-9158-3-27
5
CaoV. Y.YeY.MastwalS.RenM.CoonM.LiuQ.et al (2015). Motor learning consolidates Arc-Expressing neuronal ensembles in secondary motor cortex.Neuron861385–1392. 10.1016/j.neuron.2015.05.022
6
CorbitV. L.AhmariS. E.GittisA. H. (2017). A corticostriatal balancing act supports skill learning.Neuron96253–255. 10.1016/j.neuron.2017.09.046
7
CrittendenJ. R.TillbergP. W.RiadM. H.ShimaY.GerfenC. R.CurryJ.et al (2016). Striosome-dendron bouquets highlight a unique striatonigral circuit targeting dopamine-containing neurons.Proc. Natl. Acad. Sci. U.S.A.11311318–1132310.1073/pnas.1613337113
8
da SilvaJ. A.TecuapetlaF.PaixaoV.CostaR. M. (2018). Dopamine neuron activity before action initiation gates and invigorates future movements.Nature554244–248. 10.1038/nature25457
9
DavisM. I.PuhlH. L.III (2011). Nr4a1-eGFP is a marker of striosome-matrix architecture, development and activity in the extended striatum.PLoS One6:e16619. 10.1371/journal.pone.0016619
10
DayalV.LimousinP.FoltynieT. (2017). Subthalamic nucleus deep brain stimulation in Parkinson’s disease: the effect of varying stimulation parameters.J. Parkinsons Dis.7235–245. 10.3233/JPD-171077
11
DudmanJ. T.KrakauerJ. W. (2016). The basal ganglia: from motor commands to the control of vigor.Curr. Opin. Neurobiol.37158–166. 10.1016/j.conb.2016.02.005
12
DurieuxP. F.SchiffmannS. N.de Kerchove d’ExaerdeA. (2012). Differential regulation of motor control and response to dopaminergic drugs by D1R and D2R neurons in distinct dorsal striatum subregions.EMBO J.31640–653. 10.1038/emboj.2011.400
13
EmreM. (2003). Dementia associated with Parkinson’s disease.Lancet Neurol.2229–237. 10.1016/S1474-4422(03)00351-X
14
EvansR. C.TwedellE. L.ZhuM.AscencioJ.ZhangR.KhaliqZ. M. (2020). Functional dissection of basal ganglia inhibitory inputs onto substantia nigra dopaminergic neurons.Cell Rep.32:108156. 10.1016/j.celrep.2020.108156
15
EvansR. C.ZhuM.KhaliqZ. M. (2017). Dopamine inhibition differentially controls excitability of substantia nigra dopamine neuron subpopulations through T-Type calcium channels.J. Neurosci.373704–3720. 10.1523/JNEUROSCI.0117-17.2017
16
FearnleyJ. M.LeesA. J. (1991). Ageing and Parkinson’s disease: substantia nigra regional selectivity.Brain114 (Pt 5)2283–2301. 10.1093/brain/114.5.2283
17
FrimD. M.UhlerT. A.GalpernW. R.BealM. F.BreakefieldX. O.IsacsonO. (1994). Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat.Proc. Natl. Acad. Sci. U.S.A.915104–5108. 10.1073/pnas.91.11.5104
18
GalterD.BuervenichS.CarmineA.AnvretM.OlsonL. (2003). ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson’s disease and in the ventral tegmental area in schizophrenia.Neurobiol. Dis.14637–647. 10.1016/j.nbd.2003.09.001
19
GravesS. M.XieZ.StoutK. A.ZampeseE.BurbullaL. F.ShihJ. C.et al (2019). Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain.Nat. Neurosci.2315–20. 10.1038/s41593-019-0556-3
20
GrunblattE.RuderJ.MonoranuC. M.RiedererP.YoudimM. B.MandelS. A. (2017). Differential alterations in metabolism and proteolysis-related proteins in human Parkinson’s disease substantia Nigra.Neurotox Res.10.1007/s12640-017-9843-5
21
HelieS.EllS. W.AshbyF. G. (2015). Learning robust cortico-cortical associations with the basal ganglia: an integrative review.Cortex64123–135. 10.1016/j.cortex.2014.10.011
22
HeremansE.NackaertsE.VervoortG.BroederS.SwinnenS. P.NieuwboerA. (2016). Impaired retention of motor learning of writing skills in patients with Parkinson’s disease with freezing of gait.PLoS One11:e0148933. 10.1371/journal.pone.0148933
23
HintiryanH.FosterN. N.BowmanI.BayM.SongM. Y.GouL.et al (2016). The mouse cortico-striatal projectome.Nat. Neurosci.191100–1114. 10.1038/nn.4332
24
HookP. W.McClymontS. A.CannonG. H.LawW. D.MortonA. J.GoffL. A.et al (2018). Single-Cell RNA-Seq of mouse dopaminergic neurons informs candidate gene selection for sporadic Parkinson disease.Am. J. Hum. Genet.102427–446. 10.1016/j.ajhg.2018.02.001
25
HutchisonM. A.GuX.AdroverM. F.LeeM. R.HnaskoT. S.AlvarezV. A.et al (2018). Genetic inhibition of neurotransmission reveals role of glutamatergic input to dopamine neurons in high-effort behavior.Mol. Psychiatry231213–1225. 10.1038/mp.2017.7
26
JacobsF. M.SmitsS. M.NoorlanderC. W.von OerthelL.van der LindenA. J.BurbachJ. P.et al (2007). Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency.Development1342673–2684. 10.1242/dev.02865
27
KantakS. S.WinsteinC. J. (2012). Learning-performance distinction and memory processes for motor skills: a focused review and perspective.Behav. Brain Res.228219–231. 10.1016/j.bbr.2011.11.028
28
KimJ. I.GanesanS.LuoS. X.WuY. W.ParkE.HuangE. J.et al (2015). Aldehyde dehydrogenase 1a1 mediates a GABA synthesis pathway in midbrain dopaminergic neurons.Science350102–106. 10.1126/science.aac4690
29
KoppakaV.ThompsonD. C.ChenY.EllermannM.NicolaouK. C.JuvonenR. O.et al (2012). Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.Pharmacol. Rev.64520–539. 10.1124/pr.111.005538
30
KordowerJ. H.OlanowC. W.DodiyaH. B.ChuY.BeachT. G.AdlerC. H.et al (2013). Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease.Brain1362419–2431. 10.1093/brain/awt192
31
KupferschmidtD. A.JuczewskiK.CuiG.JohnsonK. A.LovingerD. M. (2017). Parallel, but dissociable, processing in discrete corticostriatal inputs encodes skill learning.Neuron96476–489.e5. 10.1016/j.neuron.2017.09.040
32
La MannoG.GyllborgD.CodeluppiS.NishimuraK.SaltoC.ZeiselA.et al (2016). Molecular diversity of midbrain development in mouse, human, and stem cells.Cell167566–580 e19. 10.1016/j.cell.2016.09.027
33
LangstonJ. W. (2017). The MPTP story.J. Parkinsons Dis.7S11–S19. 10.3233/JPD-179006
34
LawhornC.SmithD. M.BrownL. L. (2009). Partial ablation of mu-opioid receptor rich striosomes produces deficits on a motor-skill learning task.Neuroscience163109–119. 10.1016/j.neuroscience.2009.05.021
35
LernerT. N.ShilyanskyC.DavidsonT. J.EvansK. E.BeierK. T.ZalocuskyK. A.et al (2015). Intact-Brain analyses reveal distinct information carried by SNc dopamine subcircuits.Cell162635–647. 10.1016/j.cell.2015.07.014
36
LiuG.YuJ.DingJ.XieC.SunL.RudenkoI.et al (2014). Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.J. Clin. Invest.1243032–3046. 10.1172/JCI72176
37
MandelS. A.FishmanT.YoudimM. B. (2007). Gene and protein signatures in sporadic Parkinson’s disease and a novel genetic model of PD.Parkinsonism Relat. Disord.13 (Suppl. 3)S242–S247. 10.1016/S1353-8020(08)70009-9
38
MarchittiS. A.DeitrichR. A.VasiliouV. (2007). Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase.Pharmacol. Rev.59125–150. 10.1124/pr.59.2.1
39
MazzoniP.HristovaA.KrakauerJ. W. (2007). Why don’t we move faster? Parkinson’s disease, movement vigor, and implicit motivation.J. Neurosci.277105–7116. 10.1523/JNEUROSCI.0264-07.2007
40
McCafferyP.DragerU. C. (1994). High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system.Proc. Natl. Acad. Sci. U.S.A.917772–7776. 10.1073/pnas.91.16.7772
41
McGregorM. M.McKinseyG. L.GirasoleA. E.Bair-MarshallC. J.RubensteinJ. L. R.NelsonA. B. (2019). Functionally distinct connectivity of developmentally targeted striosome neurons.Cell Rep.291419–1428.e5. 10.1016/j.celrep.2019.09.076
42
MenegasW.BerganJ. F.OgawaS. K.IsogaiY.Umadevi VenkatarajuK.OstenP.et al (2015). Dopamine neurons projecting to the posterior striatum form an anatomically distinct subclass.Elife4:e10032. 10.7554/eLife.10032.021
43
PanJ.YuJ.SunL.XieC.ChangL.WuJ.et al (2019). ALDH1A1 regulates postsynaptic mu-opioid receptor expression in dorsal striatal projection neurons and mitigates dyskinesia through transsynaptic retinoic acid signaling.Sci. Rep.9:3602. 10.1038/s41598-019-40326-x
44
PatriarchiT.ChoJ. R.MertenK.HoweM. W.MarleyA.XiongW. H.et al (2018). Ultrafast neuronal imaging of dopamine dynamics with designed genetically encoded sensors.Science360:eaat4422. 10.1126/science.aat4422
45
PoulinJ. F.CaroniaG.HoferC.CuiQ.HelmB.RamakrishnanC.et al (2018). Mapping projections of molecularly defined dopamine neuron subtypes using intersectional genetic approaches.Nat. Neurosci.211260–1271. 10.1038/s41593-018-0203-4
46
PoulinJ. F.ZouJ.Drouin-OuelletJ.KimK. Y.CicchettiF.AwatramaniR. B. (2014). Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling.Cell Rep.9930–943. 10.1016/j.celrep.2014.10.008
47
ReesJ. N.FlorangV. R.EckertL. L.DoornJ. A. (2009). Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.Chem. Res. Toxicol.221256–1263. 10.1021/tx9000557
48
RochesterL.BakerK.HetheringtonV.JonesD.WillemsA. M.KwakkelG.et al (2010). Evidence for motor learning in Parkinson’s disease: acquisition, automaticity and retention of cued gait performance after training with external rhythmical cues.Brain Res.1319103–111. 10.1016/j.brainres.2010.01.001
49
SalinasA. G.DavisM.I.LovingerD. M.MateoY. (2016). Dopamine dynamics and cocaine sensitivity differ between striosome and matrix compartments of the striatum.Neuropharmacology108275–283. 10.1016/j.neuropharm.2016.03.049
50
SaundersA.MacoskoE. Z.WysokerA.GoldmanM.KrienenF. M.de RiveraH.et al (2018). Molecular diversity and specializations among the cells of the adult mouse brain.Cell1741015–1030.e16. 10.1016/j.cell.2018.07.028
51
SgobioC.WuJ.ZhengW.ChenX.PanJ.SalinasA. G.et al (2017). Aldehyde dehydrogenase 1-positive nigrostriatal dopaminergic fibers exhibit distinct projection pattern and dopamine release dynamics at mouse dorsal striatum.Sci. Rep.7:5283. 10.1038/s41598-017-05598-1
52
SommerW. H.CostaR. M.HanssonA. C. (2014). Dopamine systems adaptation during acquisition and consolidation of a skill.Front. Integr. Neurosci.8:87. 10.3389/fnint.2014.00087
53
SulzerD.SurmeierD. J. (2013). Neuronal vulnerability, pathogenesis, and Parkinson’s disease.Mov. Disord.2841–50. 10.1002/mds.25095
54
SunF.ZengJ.JingM.ZhouJ.FengJ.OwenS. F.et al (2018). Fluorescent sensor enables rapid and specific detection of dopamine in flies, fish, and mice.Cell174481–496.e19. 10.1016/j.cell.2018.06.042
55
SurmeierD. J.SchumackerP. T. (2013). Calcium, bioenergetics, and neuronal vulnerability in Parkinson’s disease.J. Biol. Chem.28810736–10741. 10.1074/jbc.R112.410530
56
TasicB. (2018). Single cell transcriptomics in neuroscience: cell classification and beyond.Curr. Opin. Neurobiol.50242–249. 10.1016/j.conb.2018.04.021
57
TiklovaK.BjorklundA. K.LahtiL.FiorenzanoA.NolbrantS.GillbergL.et al (2019). Single-cell RNA sequencing reveals midbrain dopamine neuron diversity emerging during mouse brain development.Nat. Commun.10:581. 10.1038/s41467-019-08453-1
58
ValentinV. V.MaddoxW. T.AshbyF. G. (2016). Dopamine dependence in aggregate feedback learning: a computational cognitive neuroscience approach.Brain Cogn.1091–18. 10.1016/j.bandc.2016.06.002
59
Vogt WeisenhornD. M.GiesertF.WurstW. (2016). Diversity matters – heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson’s Disease.J. Neurochem.139(Suppl. 1)8–26. 10.1111/jnc.13670
60
Watabe-UchidaM.ZhuL.OgawaS. K.VamanraoA.UchidaN. (2012). Whole-brain mapping of direct inputs to midbrain dopamine neurons.Neuron74858–873. 10.1016/j.neuron.2012.03.017
61
WernerC. J.Heyny-von HaussenR.MallG.WolfS. (2008). Proteome analysis of human substantia nigra in Parkinson’s disease.Proteome Sci.6:8. 10.1186/1477-5956-6-8
62
WuJ.KungJ.DongJ.ChangL.XieC.HabibA.et al (2019). Distinct connectivity and functionality of aldehyde dehydrogenase 1a1-positive nigrostriatal dopaminergic neurons in motor learning.Cell Rep.281167–1181 e7. 10.1016/j.celrep.2019.06.095
Summary
Keywords
ALDH1A1, dopamine, Parkinson’s disease, connectivity, motor learning, substantia nigra
Citation
Carmichael K, Evans RC, Lopez E, Sun L, Kumar M, Ding J, Khaliq ZM and Cai H (2021) Function and Regulation of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons in Motor Control and Parkinson’s Disease. Front. Neural Circuits 15:644776. doi: 10.3389/fncir.2021.644776
Received
21 December 2020
Accepted
26 April 2021
Published
17 May 2021
Volume
15 - 2021
Edited by
Talia Newcombe Lerner, Northwestern University, United States
Reviewed by
Yoshikazu Isomura, Tokyo Medical and Dental University, Japan; Jean-Francois Poulin, McGill University, Canada
Updates

Check for updates
Copyright
© 2021 Carmichael, Evans, Lopez, Sun, Kumar, Ding, Khaliq and Cai.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Huaibin Cai, caih@mail.nih.gov
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.